Search

everythinglearnresearchcommunity

for

Search:↓

A new compound shows promise as a topical treatment for hair loss.

ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.

Some dibenzo compounds might help treat cancer with fewer side effects.

The new compound may be a safer alternative to finasteride for prostate protection.

The research suggests Dutasteride and Solifenacin may be effective against the bacterium causing listeriosis.

The microneedle patch boosts hair growth by reducing DHT and oxidative stress.

Lenvatinib and sorafenib are generally safe but need dose adjustments due to side effects.

Agouti protein affects melanocortin receptors through competitive antagonism and receptor down-regulation.

Spironolactone reduces the number of androgen receptor sites in rat skin by blocking them with its metabolite.

Stopping the beta-blocker nadolol led to quick hair regrowth and improved scalp condition.

Prolactin affects the production of different keratins in human hair, which could lead to new treatments for skin and hair disorders.

Compounds 15, 20, and 25 are strong inhibitors of human steroid 5α-reductase type 2.

Ruxolitinib cream effectively treats skin conditions like atopic dermatitis and vitiligo with minimal side effects.

Certain changes to the B-ring of androgen receptor ligands can increase their effectiveness for potential treatments of muscle and bone conditions.

Keratin 6A increases skin inflammation, suggesting it could be a target for treating certain skin diseases.

These medications for BPH have known risks and may have new side effects.

Quercitrin may help treat Alzheimer's by boosting brain cell signaling without causing tumors.

Tralokinumab for atopic dermatitis may cause side effects like dizziness, headache, nausea, hair loss, and acne.

Afatinib often causes skin problems that need proactive management.

Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.

Stopping JAK inhibitor treatment for hair loss can lead to worse hair loss than before the treatment.

The L457(3.43)R mutation in the human lutropin receptor causes increased activity and hormone insensitivity, leading to precocious puberty.

Some gonadal hormone drugs can block filovirus entry into cells.

Blocking TRPV3 may help treat itch in dry skin conditions.

CLK1 is needed for skin cells to become epidermal cells but not sebocytes.

Some new isatin compounds could be strong cancer-fighting drugs because they fit well in cancer-related proteins and have good drug-like properties.

JAK inhibitors may reduce depression in people with alopecia areata.

Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.